Delving into the Latest Updates on NCR-102 with Synapse

Overview

Basic Info

Drug Type

Induced pluripotent stem cells (iPSC), Mesenchymal stem cell therapy

Synonyms

NCR 102, NCR102

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesOther Diseases

Active Indication

Acute Graft Versus Host DiseaseRefractory Acute Graft Versus Host Disease

Inactive Indication-

Originator Organization

Nuwacell Biotechnologies Co., Ltd.

Active Organization

Nuwacell Biotechnologies Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

主要目的： Ⅰ期：评价NCR102注射液在II-IV度消化道受累的aGVHD患者中的安全性。次要目的： Ⅰ期：评价NCR102注射液在II-IV度消化道受累的aGVHD患者中的初步有效性、细胞动力学特征（CK）、免疫原性；探索与NCR102注射液临床疗效或作用机理相关的生物标志物。

[Translation]

Primary objective: Phase I: To evaluate the safety of NCR102 injection in patients with aGVHD with II-IV degree gastrointestinal involvement. Secondary objective: Phase I: To evaluate the preliminary efficacy, cell kinetic characteristics (CK), and immunogenicity of NCR102 injection in patients with aGVHD with II-IV degree gastrointestinal involvement; to explore biomarkers related to the clinical efficacy or mechanism of action of NCR102 injection.

Start Date09 May 2025

Sponsor / Collaborator

Nuwacell Biotechnologies Co., Ltd.

[+1]

100 Clinical Results associated with NCR-102

Login to view more data

100 Translational Medicine associated with NCR-102

Login to view more data

100 Patents (Medical) associated with NCR-102

Login to view more data

100 Deals associated with NCR-102

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Graft Versus Host Disease	Phase 2	-	Nuwacell Biotechnologies Co., Ltd.	28 Apr 2025
Refractory Acute Graft Versus Host Disease	IND Approval	China	Nuwacell Biotechnologies Co., Ltd.	20 Mar 2025